Immunogenicity of 13-valent pneumococcal conjugate vaccine in immunocompetent older adults with stable underlying medical conditions

The 13-valent pneumococcal conjugate vaccine (PCV13) elicits robust functional antibody responses in immunocompetent adults aged 50 years, including healthy adults and those considered at risk (ie, stable, chronic cardiovascular disease, pulmonary disease, or diabetes mellitus). This analysis is consistent with data suggesting immunocompetent at-risk populations aged 50 years produce functional antipneumococcal antibody responses to PCV13 comparable to those not at risk. An OPA titer that correlates with protection has not been defined for adults; however, PCV13 elicits generally higher responses than the 23-valent pneumococcal polysaccharide vaccine (PPSV23) one month after vaccination. PCV13 vaccination of immunocompetent at-risk populations likely results in benefits analogous to those without additional risk.